№ files_lp_4_process_1_27850
File format: docx Character count: 17459 File size: 156 KB
Defines the legal and procedural framework for the supply of azithromycin to prevent diphtheria in high-risk settings or outbreaks, specifying authorized practitioners, required organizational approvals, and version-specific operational guidelines.
Year: 2022
Region / country: United Kingdom
Topic: Public health; infectious disease prevention
Document type: Patient Group Direction (PGD)
Organization: UK Health Security Agency (UKHSA)
Authors: Jacqueline Lamberty, Mary Ramsay, Kate Wedgwood
Target audience: Registered healthcare practitioners
Valid from: 21 November 2022
Review date: 21 May 2024
Expiry date: 20 November 2024
Version: 02.00
Changes history: Removal of Sandoz as exclusive brand, addition of off-label use for Pfizer suspension, guidance for suspension handling
Authorization requirements: Named practitioner authorization under current PGD version, organizational sign-off according to HMR2012
Training requirements: Competency in PGDs, product familiarity, local policy training compliance
Source type: Regulatory/healthcare guidance document
PGD development: Peer-reviewed by expert panel and ratified by UKHSA Clinical Quality Oversight Board
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Azithromycin Tablets for Prevention of Exacerbations of COPD and Bronchiectasis: GP Communication Letter
Document type: Clinical correspondence letter
Medical topic: COPD and bronchiectasis management
Medication: Azithromycin
Purpose: Recommendation to initiate azithromycin therapy to reduce exacerbations
Sender role: Respiratory specialist
Recipient role: General Practitioner
Patient category: Patients with COPD or bronchiectasis experiencing exacerbations
Clinical objective: Reduction in number of exacerbations within a 12-month period
Review schedule: 6 months after treatment initiation and additional follow-up months as specified
Prescribing status: Amber Recommended
Prescribing guidance source: Pan-Mersey Area Prescribing Committee
Response requirement: GP confirmation or refusal within 14 days
Sections included: Treatment dose and frequency, indication, review plan, GP decision section
Diphtheria, Tetanus, Acellular Pertussis and Inactivated Poliomyelitis Vaccine Patient Group Direction (PGD)
Year: 2025
Region / City: England
Topic: Immunisation
Document Type: Patient Group Direction (PGD)
Organisation / Institution: UK Health Security Agency (UKHSA)
Author: Suki Hunjunt, Rebecca Cordery, Greta Hayward
Target Audience: Healthcare practitioners
Period of Validity: From 1 November 2025 to 1 November 2028
Approval Date: 24 September 2025
Revision Date: 23 September 2025
Standard Operating Procedure for Diphtheria Toxin
Note: Year
Topic: Diphtheria Toxin Handling and Safety Protocol
Document Type: Standard Operating Procedure
Target Audience: Researchers, Laboratory Personnel
Diphtheria Toxin (DT) Safety Protocols
Year: 2023
Region / City: Berkeley, CA
Topic: Biosafety, Laboratory Procedures, Toxicology
Document Type: Standard Operating Procedure (SOP)
Institution: University of California, Berkeley
Author: EH&S
Target Audience: Researchers, Laboratory Personnel, Biosafety Officers
Period of Validity: Ongoing
Approval Date: 2023
Amendment Date: Not provided
Combination Diphtheria, Tetanus and Pertussis – Polio (DTaP-IPV) Vaccine Protocol for Persons Age 4 through 6 years
Year: 2024
Region / City: United States
Topic: Vaccination Protocol
Document Type: Medical Protocol
Organization / Institution: American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP)
Author: Prescriber
Target Audience: Healthcare professionals
Period of validity: Indefinite until rescinded
Approval Date: March 26, 2024
Date of changes: Not specified
PATIENT GROUP DIRECTION (PGD) Administration of diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine (DTaP/IPV/Hib) Individuals from 8 weeks to under 10 years of age in accordance with the national immunisation programme
Year: 2015
Region / city: United Kingdom
Topic: Immunisation
Document type: Public Health Guideline
Organization / institution: Public Health England
Author: Elizabeth Graham, Mary Ramsay, David Green
Target audience: Healthcare professionals, Registered Nurses, Paramedics
Period of validity: From 15 December 2015 to 30 November 2017
Approval date: 15 December 2015
Amendment date: N/A
Expiry date: 30 November 2017
Version: v01.00
Review date: 1 June 2017
Reference number: DTaP/IPV/Hib PGD
Note: Change history
Version 1.00: New PHE PGD template, 15 December 2015
Topics: 0200 azithromycin Diphtheria